scholarly journals Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer

2014 ◽  
Vol 20 (42) ◽  
pp. 15580 ◽  
Author(s):  
Xiao-Yi Wang
Keyword(s):  
Pancreatic Cancer ◽  
Metabolic Response ◽  
Pet Ct

scholarly journals Evaluation of the Metabolic Response to Cyclopamine Therapy in Pancreatic Cancer Xenografts Using a Clinical PET-CT System

2012 ◽  
Vol 5 (5) ◽  
pp. 335-343 ◽  
Author(s):  
Hany Kayed ◽  
Patrick Meyer ◽  
Yong He ◽  
Bettina Kraenzlin ◽  
Christian Fink ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Metabolic Response ◽  
Pet Ct ◽  
Ct System

PET/CT IN THE DIAGNOSIS OF PANCREATIC CANCER: LITERATURE REVIEW

2018 ◽  
pp. 57-67
Author(s):  
P. E. Tulin ◽  
M. B. Dolgushin ◽  
D. I. Nevzorov ◽  
P. V. Kochergin ◽  
Yu. I. Patyutko
Keyword(s):  
Pancreatic Cancer ◽  
Literature Review ◽  
Pancreatic Neoplasms ◽  
Poor Prognosis ◽  
Modern Imaging ◽  
Pet Ct

Pancreatic cancer has a poor prognosis, often because most pancreatic neoplasms are found to be unresectable at diagnosis. Early staging of the tumor process can change the tactics of treatment and affect the survival of patients. The purpose of this review is to provide an overview of pancreatic cancer and the role of modern imaging in its diagnosis with an emphasis on PET/CT with a various radiopharmaceuticals.

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

scholarly journals Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 971
Author(s):  
Cecilia Marini ◽  
Matteo Bauckneht ◽  
Anna Borra ◽  
Rita Lai ◽  
Maria Isabella Donegani ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Cox Regression ◽  
Metabolic Response ◽  
Progression Free Survival ◽  
Disease Relapse ◽  
Cox Regression Analysis ◽  
Normal Tissues ◽  
Pet Ct ◽  
Genome Sharing

Genome sharing between cancer and normal tissues might imply a similar susceptibility to chemotherapy toxicity. The present study aimed to investigate whether curative potential of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is predicted by the metabolic response of normal tissues in patients with Hodgkin lymphoma (HL). METHODS: According to current guidelines, 86 patients with advanced-stage (IIB-IVB) HL, prospectively enrolled in the HD0607 trial (NCT00795613), underwent 18 F-fluorodeoyglucose PET/CT imaging at diagnosis and, at interim, after two ABVD courses, to decide regimen maintenance or its escalation. In both scans, myocardial FDG uptake was binarized according to its median value. Death and disease relapse were recorded to estimate progression-free survival (PFS) during a follow-up with median duration of 43.8 months (range 6.97–60). RESULTS: Four patients (4.6%) died, while six experienced disease relapse (7%). Complete switch-off of cancer lesions and cardiac lighting predicted a favorable outcome at Kaplan–Mayer analyses. The independent nature and additive predictive value of their risk prediction were confirmed by the multivariate Cox regression analysis. CONCLUSION: Susceptibility of HL lesions to chemotherapy is at least partially determined by factors featuring the host who developed it.

Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

2019 ◽  
Vol 44 (7) ◽  
pp. 578-579 ◽  
Author(s):  
Karim Amrane ◽  
Luc Ollivier ◽  
Pierre-Yves Salaun ◽  
Jean-Philippe Metges ◽  
Ronan Abgral
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Line Treatment ◽  
Second Line ◽  
Complete Metabolic Response ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer

Pancreas ◽  
2013 ◽  
Vol 42 (1) ◽  
pp. 11-19 ◽  
Author(s):  
Akinori Asagi ◽  
Koji Ohta ◽  
Junichirou Nasu ◽  
Minoru Tanada ◽  
Seijin Nadano ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fdg Pet ◽  
Clinical Management ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals 18F- FDG PET/CT helps differentiate autoimmune pancreatitis from pancreatic cancer

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Jian Zhang ◽  
Guorong Jia ◽  
Changjing Zuo ◽  
Ningyang Jia ◽  
Hui Wang
Keyword(s):  
Pancreatic Cancer ◽  
Autoimmune Pancreatitis ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement

2000 ◽  
Vol 98 (4) ◽  
pp. 389-399 ◽  
Author(s):  
Matthew D. BARBER ◽  
Donald C. MCMILLAN ◽  
Tom PRESTON ◽  
James A. ROSS ◽  
Kenneth C. H. FEARON
Keyword(s):  
Pancreatic Cancer ◽  
Body Weight ◽  
Energy Expenditure ◽  
Fish Oil ◽  
Cancer Patients ◽  
Metabolic Response ◽  
Resting Energy Expenditure ◽  
Fat Oxidation ◽  
Nutritional Supplement ◽  
Healthy Control

Weight-losing patients with advanced cancer often fail to gain weight with conventional nutritional support. This suboptimal response might be explained, in part, by an increased metabolic response to feeding. It has been suggested that eicosapentaenoic acid (EPA) can modify beneficially the metabolic response to cancer. The aim of the present study was to examine the metabolic response to feeding in cancer and the effects of an EPA-enriched oral food supplement on this response. A total of 16 weight-losing, non-diabetic patients with unresectable pancreatic adenocarcinoma and six healthy, weight-stable controls were studied by indirect calorimetry in the fasting and fed states. Body composition was estimated by bioimpedence analysis. Cancer patients were then given a fish-oil-enriched nutritional supplement providing 2 g of EPA and 2550 kJ daily, and underwent repeat metabolic study after 3 weeks of such supplementation. At baseline, resting energy expenditure whether expressed per kg body weight, lean body mass or body cell mass was significantly greater in the cancer patients compared with controls. Fat oxidation was significantly higher in the fasting state in cancer patients [median 1.26 g·kg-1·min-1 (interquartile range 0.95–1.38)] than in controls [0.76 g·kg-1·min-1 (0.62–0.92); P < 0.05]. Over the 4 h feeding period, changes in insulin and glucose concentrations in cancer patients suggested relative glucose intolerance. In response to oral meal feeding, the percentage change in the area under the curve of energy expenditure was significantly lower in the cancer patients [median 7.9% (interquartile range 3.4–9.0)] than in controls [12.6% (9.9–15.1); P < 0.01]. After 3 weeks of the EPA-enriched supplement, the body weight of the cancer patients had increased and the energy expenditure in response to feeding had risen significantly [9.6% (6.3–12.4)], such that it was no different from baseline healthy control values. Similarly, fasting fat oxidation fell to 1.02 g·kg-1·min-1 (0.8–1.18), again no longer significantly different from baseline healthy control values. While weight-losing patients with advanced pancreatic cancer have an increased resting energy expenditure and increased fat oxidation, the energy cost of feeding is, in fact, reduced. Provision of a fish-oil-enriched nutritional supplement results in some normalization of the metabolic response in both the fasted and fed states, in association with an improvement in nutritional status.

scholarly journals Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer

Medicine ◽  
2016 ◽  
Vol 95 (19) ◽  
pp. e3686 ◽  
Author(s):  
Hyung-Jun Im ◽  
Suthet Oo ◽  
Woohyun Jung ◽  
Jin-Young Jang ◽  
Sun-Whe Kim ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Resectable Pancreatic Cancer ◽  
Pet Ct ◽  
Fdg Pet Ct

P.10.7 THE VALUE OF (18)FDG-PET/CT IN PATIENTS WITH RESECTABLE PANCREATIC CANCER: A PROSPECTIVE STUDY

2013 ◽  
Vol 45 ◽  
pp. S160 ◽  
Author(s):  
S. Crippa ◽  
M. Salgarello ◽  
S. Laiti ◽  
S. Partelli ◽  
C. Zardini ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prospective Study ◽  
Fdg Pet ◽  
Resectable Pancreatic Cancer ◽  
Pet Ct ◽  
A Prospective Study ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document